Research parameters | Aducanumab | SoC | References | Disturubution |
---|---|---|---|---|
Costs-Annual ($) | Mild $22,000* | Mild $3,140# Moderate $9,460# Severe $16.956# | Gamma | |
Effectiveness data | Mild 0.73 | Mild 0.73 Moderate 0.69 Severe 0.27 | [35] | Beta |
Model and transition probabilities | [32] | Beta | ||
Number of cohorts | 1000 | 1000 | Â | NA |
Clinical efficacy data | RR = 0.6 | – | Assumption | NA |
Horizon | 5Â year | 5Â year | Â | NA |
Discount Rate | 6% | 6% | [37] | (3–9%) |
Threshold Value+ | $28,617 | $28,617 | [38] | NA |
Perspective | Patient | Patient |  | – |